HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients-Reference-Cited by-同舟云学术

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

Published:2016-06-18 Issue:1 Volume:158 Page:99-111
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Kurozumi Sasagu,Padilla Mary,Kurosumi Masafumi,Matsumoto Hiroshi,Inoue Kenichi,Horiguchi Jun,Takeyoshi Izumi,Oyama Tetsunari,Ranger-Moore Jim,Allred D. Craig,Dennis Eslie,Nitta Hiroaki

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-3856-2.pdf

Reference54 articles.

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917

2. Bertos NR, Park M (2011) Breast cancer—one term, many entities? J Clin Invest 121:3789–3796

3. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516

4. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655

5. Francis GD, Jones MA, Beadle GF, Stein SR (2009) Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 18:88–95

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer;Pathology - Research and Practice;2024-08

2. Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer;Medical Molecular Morphology;2024-04-15

3. Targeting HER2 heterogeneity in breast and gastrointestinal cancers;Trends in Cancer;2023-11

4. Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib;Breast Cancer: Targets and Therapy;2023-07

5. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04;Frontiers in Public Health;2023-06-30